RecruitingNCT06608511
Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers
Sponsor
University of Wisconsin, Madison
Enrollment
20 participants
Start Date
Dec 11, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
The goal of this observational study is to study blood samples and compare them to other biospecimens and clinical outcomes in participants who have melanoma or non-melanoma skin cancers. The main question it aims to answer is: * Are blood based signatures able to predict progression-free survival (PFS)? Participants undergoing regular treatment for their skin cancer will provide blood samples.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Age ≥18 years.
- Participants must meet at least one of the following criteria:
- Finding suspicious of melanoma or non-melanoma skin cancer based on clinical, radiographic, or laboratory findings. Non-melanoma skin cancers include: basal cell carcinoma, cutaneous squamous cell carcinoma, and Merkel cell carcinoma.
- A confirmed diagnosis of melanoma or non-melanoma skin cancer.
Exclusion Criteria2
- Vulnerable populations, including pregnant women, those who lack consent capacity, the mentally ill, prisoners, cognitively impaired persons, children (age \<18), and UW employees that report to the investigator(s) or to study team members.
- Not suitable for study participation due to other reasons at the discretion of the investigators.
Interventions
OTHERBlood draw for the laboratory assessment
Participants will have 50 milliliters (3.5 tablespoons) of blood drawn
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06608511
Related Trials
Early Phase Study of KESONOTIDE™in Participants With Solid Tumours
NCT069260753 locations
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
NCT072879178 locations
A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks
NCT074697091 location
A Phase II Clinical Trial on Neo-adjuvant Pembrolizumab in Patients With pT3b-T4a/b cN0M0 Melanoma.
NCT074488311 location
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
NCT0658541048 locations